Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowIn Q3 2024, Zoetis (ZTS) reported a 14% operational revenue growth, driven by a 15% increase in the U.S. and a 13% increase internationally. Adjusted net income saw a 15% operational rise, with key franchises, including the companion animal portfolio, also growing by 15%. The osteoarthritis pain franchise, consisting of Librela and Solensia, delivered a significant 97% operational revenue increase globally. This consistent growth reflects demand for their diverse and science-driven portfolio, positioned to address customer needs effectively.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Zoetis Inc. (ZTS)
Zoetis is the world’s largest animal-health company.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
ZTS stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
